Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

2.

Intravenous buprenorphine self-administration by detoxified heroin abusers.

Comer SD, Collins ED, Fischman MW.

J Pharmacol Exp Ther. 2002 Apr;301(1):266-76.

3.
4.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

5.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004.

6.

Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

Comer SD, Walker EA, Collins ED.

Psychopharmacology (Berl). 2005 Oct;181(4):664-75.

7.

The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Jones JD, Madera G, Comer SD.

Pharmacol Biochem Behav. 2014 Jul;122:299-306. doi: 10.1016/j.pbb.2014.04.012.

8.

Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.

Comer SD, Collins ED, Fischman MW.

Psychopharmacology (Berl). 2001 Feb;154(1):28-37.

PMID:
11292003
9.

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD.

Addict Biol. 2015 Jul;20(4):784-98. doi: 10.1111/adb.12163.

10.

Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.

Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ.

Neuropsychopharmacology. 2008 Apr;33(5):1179-91.

11.

Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance.

Greenwald MK, Johanson CE, Schuster CR.

Drug Alcohol Depend. 1999 Oct 1;56(3):191-203.

PMID:
10529021
12.

Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.

Becker WC, Ganoczy D, Fiellin DA, Bohnert AS.

J Subst Abuse Treat. 2015 Jan;48(1):128-31. doi: 10.1016/j.jsat.2014.09.007.

PMID:
25312475
13.

Effects of an alternative reinforcer on intravenous heroin self-administration by humans.

Comer SD, Collins ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW.

Eur J Pharmacol. 1998 Mar 12;345(1):13-26.

PMID:
9593589
14.

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333.

15.

Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.

Vicknasingam B, Dazali MN, Singh D, Schottenfeld RS, Chawarski MC.

Drug Alcohol Depend. 2015 Jul 1;152:164-9. doi: 10.1016/j.drugalcdep.2015.04.007.

PMID:
25935736
16.

Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2010 Aug;211(3):303-12. doi: 10.1007/s00213-010-1898-4.

17.

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG.

J Subst Abuse Treat. 2000 Apr;18(3):277-81.

PMID:
10742642
18.

The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.

Jones JD, Sullivan MA, Manubay J, Vosburg SK, Comer SD.

Neuropsychopharmacology. 2011 Jan;36(2):411-22. doi: 10.1038/npp.2010.172.

19.

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D; BHIVES Collaborative..

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.

20.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8.

Items per page

Supplemental Content

Support Center